139 related articles for article (PubMed ID: 35489119)
1. Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen.
Wu W; Ren K; Li N; Luo Q; Xu C; Zou L
Transl Oncol; 2022 Jul; 21():101437. PubMed ID: 35489119
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
3. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
Wu W; Chen X; Li N; Luo Q; Zou L
Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
[TBL] [Abstract][Full Text] [Related]
4. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
5. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
[No Abstract] [Full Text] [Related]
7. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
8. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
9. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
10. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
11. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
12. [Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].
Chen F; Shen CX; Wang HG; Li GX; Wang XQ; Wen Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(5):327-333. PubMed ID: 29871255
[No Abstract] [Full Text] [Related]
13. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
14. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
15. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.
Chen X; Zhao S; Wang H; Fu C; Tian R; Zou L
Quant Imaging Med Surg; 2021 Apr; 11(4):1220-1233. PubMed ID: 33816162
[TBL] [Abstract][Full Text] [Related]
19. A neutrophil/lymphocyte Ratio as a Significant Predictor for Patients with low-risk and early-stage Extranodal NK-T-cell Lymphoma.
Wu W; Chen X; Li N; Luo Q; Zou L
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):228-236. PubMed ID: 37006977
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Characteristics and Prognostic Analysis of Extranodal NK/T-Cell Lymphoma Patients Treated with Pegaspargase Based Chemotherapy].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):735-740. PubMed ID: 34105466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]